This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ASM journals Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ishida, K Articles by Tomono, K Search for Related Content PubMed PubMed Citation Articles by Ishida, K Articles by Tomono, K

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1994 April; 38(4): 790-798

In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae.

K Ishida, M Kaku, K Irifune, R Mizukane, H Takemura, R Yoshida, H Tanaka, T Usui, N Suyama and K Tomono

Department of Laboratory Medicine, Nagasaki University School of Medicine, Japan.

ABSTRACT

We investigated the in vitro and in vivo activities of macrolides against Mycoplasma pneumoniae. In vitro MICs of azithromycin, erythromycin, clarithromycin, and roxithromycin were determined. Azithromycin was the most potent antimicrobial agent tested in vitro. Its MIC for 90% of the strains was 0.00024 micrograms/ml. MICs for 90% of the strains of erythromycin, clarithromycin, and roxithromycin were 0.0156, 0.0078, and 0.03125 micrograms/ml, respectively. In vivo activities were assessed in a pulmonary infection model with Syrian golden hamsters. We evaluated the in vivo effects on reduction of viable M. pneumoniae cell counts and on reduction of microscopic and macroscopic histopathologies for azithromycin, erythromycin, and clarithromycin given at 10 mg/kg once daily for 1 and 3 days and given at 15 mg/kg twice daily for 2.5 and 5 days. Azithromycin was significantly more effective than erythromycin or clarithromycin in the same regimens. Especially at 10 mg/kg once daily for 1 day, only azithromycin was significantly effective in the reduction of viable M. pneumoniae cells and histopathologies. These results show that azithromycin is more efficacious than the other drugs tested against M. pneumoniae pneumonia in hamsters. These data suggest that clinical studies of macrolides in human patients are warranted.

---

Antimicrob Agents Chemother. 1994 April; 38(4): 790-798

This article has been cited by other articles:

• Waites, K. B., Crabb, D. M., Duffy, L. B. (2003). In Vitro Activities of ABT-773 and Other Antimicrobials against Human Mycoplasmas. Antimicrob. Agents Chemother. 47: 39-42 [Abstract] [Full Text]  
• Paladino, J. A., Gudgel, L. D., Forrest, A., Niederman, M. S. (2002). Cost-Effectiveness of IV-to-Oral Switch Therapy: Azithromycin vs Cefuroxime With or Without Erythromycin for the Treatment of Community-Acquired Pneumonia. Chest 122: 1271-1279 [Abstract] [Full Text]  
• Kenny, G. E., Cartwright, F. D. (2001). Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, Dalfopristin, Dirithromycin, Evernimicin, Gatifloxacin, Linezolid, Moxifloxacin, Quinupristin-Dalfopristin, and Telithromycin Compared to Their Susceptibilities to Reference Macrolides, Tetracyclines, and Quinolones. Antimicrob. Agents Chemother. 45: 2604-2608 [Abstract] [Full Text]  
• Izumikawa, K., Hirakata, Y., Yamaguchi, T., Yoshida, R., Tanaka, H., Takemura, H., Maesaki, S., Tomono, K., Kaku, M., Izumikawa, K.-I., Kamihira, S., Kohno, S. (1998). In Vitro Activities of Quinupristin-Dalfopristin and the Streptogramin RPR 106972 against Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 42: 698-699 [Abstract] [Full Text]